Results 111 to 120 of about 3,377,134 (229)

Intravenous Oxytocin Does Not Affect Glucose‐Regulating Hormones or Markers of Bone Turnover During Graded Glucose Infusion in Healthy Men

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Oxytocin has been proposed to exert glucose‐stabilising effects via modulation of pancreatic hormone secretion and to play a role in bone homeostasis. However, human data under controlled conditions are limited. We investigated the effects of intravenously infused oxytocin during a graded glucose infusion on glucose‐regulating hormones and
Vivian Kliim‐Hansen, Ida M. Gether, Aliya M. Thomas, Anne‐Marie Ellegaard, Miriam G. Pedersen, Jens J. Holst, Bolette Hartmann, Filip K. Knop, Lærke S. Gasbjerg, Asger B. Lund   +9 more
wiley   +1 more source

Increased glucose-dependent insulinotropic polypeptide (GIP) secretion in acromegaly

, 2001
Objective: Acromegaly is often associated with fasting and postprandial hyperinsulinemia, and the mechanisms involved are only partly understood. Hypersecretion of incretins such as glucose-dependent insulinotropic polypeptide (GIP) could play a role in ...
C. Gebbia, C. Pagliari, P. Bucciarelli, P. Epaminonda, M. Arosio, S. Manenti, S. Porretti, M. Peracchi   +7 more
core   +2 more sources

GLP‐1 Receptor Agonists Post‐Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims No studies have investigated the synergistic effectiveness of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1RAs) in patients with persistent obesity following bariatric surgery. The GLP‐1 Receptor Agonists Post‐Bariatric Surgery (GRABS) Trial aims to investigate the effectiveness of tirzepatide (TRZ) versus standard of care (SOC) after ...
J. M. Samuels, C. R. Williams, M. B. Patel, W. H. Self, L. M. Funk, C. Roumie, M. D. Spann, C. J. Northup, F. Ye, R. Irlmeier, I. Sohn, Y. Zhu, K. Niswender   +12 more
wiley   +1 more source

Le récepteur CCK2 dans les cancers : ciblage diagnostique et thérapeutique grâce à la vectorisation de nanoparticules magnétiques [PDF]

, 2012
Le récepteur CCK2 est un récepteur à 7 domaines transmembranaires couplé aux protéines G. D'un point de vue physiologique, le récepteur CCK2 joue un rôle central dans la régulation de la digestion, et agit également au niveau du système nerveux central ...
Sanchez, Claire
core  

Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain

, 2011
The glucose-dependent insulinotropic polypeptide receptor (GIPr) has been implicated in high fat diet-induced obesity and is proposed as an anti-obesity target despite an uncertainty regarding the mechanism of action.
Peter Thams, Pedersen, Jens, Holst, Peter Johannes, Signe Marie Jørgensen, Jens Juul Holst, Holst, Jens Juul, Hanne-Louise Kissow, Rosenkilde, Mette Marie, Füchtbauer, Ernst-Martin, Kissow, Hannelouise, Jørgensen, Signe Marie, Randi Ugleholdt, Steen Seier Poulsen, Nikolaj Nytofte, Ernst-Martin Füchtbauer, Nytofte, Nikolaj, Poulsen, Steen Seier, Jens Pedersen, Yutaka Seino, Bassi, Maria Rosaria, Mette Marie Rosenkilde, Ugleholdt, Randi, Peter Johannes Holst, Thams, Peter, Seino, Yutaka, Maria Rosaria Bassi   +25 more
core   +1 more source

Glucose-Dependent Insulinotropic Polypeptide Is Involved in Postprandial Regulation of Splanchnic Blood Supply

Administration of the gut hormone glucose-dependent insulinotropic polypeptide (GIP) increases splanchnic blood flow. We investigated the role of endogenous GIP in splanchnic blood flow regulation using a receptor antagonist in humans.
Hartmann, Bolette, Nielsen, Sophie W., Johannesen, Helle Hjorth, Gasbjerg, Lærke S., Larsson, Henrik B W, Holst, Jens J., Haddock, Bryan, Vestergaard, Mark B., Rasmussen, Rasmus S., Asmar, Ali, Andersen, Ulrik B., Langberg, Ludvig S., Østergaard, Frederikke, Skov-Jeppesen, Kirsa, Rosenkilde, Mette M.   +14 more
core   +1 more source

Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.

, 2005
Exploitation of glucose-dependent insulinotropic polypeptide (GIP) is hindered by its short biological half-life and rapid renal clearance. To circumvent these problems, two novel acylated N-terminally modified GIP analogues, N-pGluGIP(LysPAL16) and N ...
Flatt, P.R., Gault, V.A., Harriott, Patrick, Bailey, C.J., O'Harte, F.P.M., Irwin, Nigel, Green, Brian, Gault, Victor A., Flatt, Peter R., Irwin, N., Green, Brian D., Greer, Brett, Bailey, Clifford J., O'Harte, Finbarr P.M.   +13 more
core   +1 more source

Role of glucagon in metabolic diseases

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Currently, diabetes is defined as “a chronic hyperglycemic state resulting from the absolute or relative insufficiency of insulin action,” emphasizing its characterization as an insulin‐related disease. However, glucagon dysregulation should also play a critical role in the pathophysiology of type 2 diabetes.
Tadahiro Kitamura, Yoko Tabei, Masaki Kobayashi   +2 more
wiley   +1 more source

Evaluation of a rare glucose-dependent insulinotropic polypeptide receptor variant in a patient with diabetes

, 2019
AIMS: Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone that augments insulin secretion in pancreatic β-cells via its glucose-dependent insulinotropic polypeptide receptor (GIPR).
Völzke, H., Alexander Teumer, Völzke, Henry, Kühnen, Peter, Khajavi, Noushafarin, Kleinau, G., Susanna Wiegand, Wiegand, S., Gong, M., Gunnar Kleinau, Homuth, G., Heike Biebermann, Scheerer, Patrick, Jacobi, S.F., Kühnen, P., Henry Völzke, Homuth, Georg, Kleinau, Gunnar, Georg Homuth, Maolian Gong, Patrick Scheerer, Simon F. Jacobi, Scheerer, P., Teumer, A., Biebermann, H., Peter Kühnen, Jacobi, Simon F., Noushafarin Khajavi, Raile, K., Raile, Klemens, Teumer, Alexander, Krude, Heiko, Khajavi, N., Biebermann, Heike, Krude, H., Klemens Raile, Gong, Maolian, Heiko Krude, Wiegand, Susanna   +38 more
core   +1 more source

Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?

Journal of Internal Medicine, EarlyView.
Abstract Hypocholesterolemia is perceived as benign given its association with lower cardiovascular risk. However, genetic and epidemiological evidence indicates that persistently low levels of low‐density lipoprotein cholesterol (LDL‐C) and apolipoprotein B (ApoB) arise from distinct biological mechanisms with different hepatic implications ...
Valentina Flagiello, Emelie Barreby, Umberto Vespasiani‐Gentilucci, Stefano Romeo   +3 more
wiley   +1 more source